A long-running cholesterol drug dispute between Amgen and Sanofi in 2020 will return to the same federal court that killed off one test for determining how antibodies can be patented.
The case is important for drugmakers and biotechnology companies because it comes in the wake of the U.S. Court of Appeals for the Federal Circuit’s 2017 decision narrowing the patents companies can claim for the antibodies they discover. That called into question many existing biotech patents. Patent attorneys are closely watching the Amgen and Sanofi dispute to see if the court adds new restrictions.
“The decision does have the potential ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.